Medical Advocates
Brecanacir
  Main Page

New and Noteworthy
Journal Data
Conference Data


 		  
ARV Investigational  Drugs Main Page Drugs Main Page Home Page      
Last Update:  March 11, 2015 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
September 2007
 
Journal Papers, Abstracts, and Commentaries
 
In Vitro Studies
 
  In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type
1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against
a Panel of Protease Inhibitor-Resistant HIV.
Hazen R, Harvey R, Ferris R, et al  
Antimicrob Agents Chemother. 2007 Sep;51(9):3147-54.
 Abstract
 
Pharmacokinetics
 
  Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1
protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects
Reddy YS, Ford SL, Anderson MT, et al
Antimicrob Agents Chemother. 2007 Apr;51(4):1202-8.
 Abstract
 
FULL TEXT ARTICLE
Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus
protease inhibitor.
 Ford SL, Reddy YS, Anderson MT, et al
 Antimicrob Agents Chemother. 2006 Jun;50(6):2201-6.
 Paper
 
Efficacy
 
  A WEEK-IN-REVIEW FEATURED REPORT
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor:
24 week data from study HPR10006.
Lalezari JP, Ward DJ, Tomkins SA, Garges HP.
J Antimicrob Chemother. 2007 May 8;
 Abstract
Conference Reports, Abstracts,  and Posters
     
14th Conference on Retroviruses and Opportunistic Infections
 
XVI International AIDS Conference
 

ARV Investigational  Drugs Main Page Drugs Main Page Home Page      

Brecanavir